Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

MLA

Selvarangan Ponnazhagan, et al. Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.c.6542037.v1.

APA

Selvarangan Ponnazhagan, Jessy S. Deshane, Yong Wang, Vinayak Khattar, Joo Hyoung Lee, Jonathan A. Hensel, Reading Ashton, & Hong Wang. (2023). Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. https://doi.org/10.1158/1535-7163.c.6542037.v1

Chicago

Selvarangan Ponnazhagan, Jessy S. Deshane, Yong Wang, Vinayak Khattar, Joo Hyoung Lee, Jonathan A. Hensel, Reading Ashton, and Hong Wang. 2023. “Data from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity,” April. doi:10.1158/1535-7163.c.6542037.v1.